SERPINA1 and graft versus host disease: Examples are treatment with anti-LPS37, HSP90-inhibitor 17AAG38, locked nucleic acid anti-miRNA-29a39, uricase for uric acid40, apyrase for ATP41, NecroX-7 for HMGB1 blockade42 and alpha-1-antitrypsin (AAT) targeting heparin sulfate43, all of which have been shown to reduce GVHD in mouse models and AAT in addition SR-GVHD in humans44.